{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:16:17Z","timestamp":1773310577038,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Neuromyelitis optica spectrum disease (NMOSD) is a rare autoimmune disorder of the central nervous system characterized by optic neuritis, myelitis, or brain lesions. Its symptoms overlap with those of multiple sclerosis (MS), making a diagnosis of NMOSD challenging. Here, we report a rare case of NMOSD-induced complete spinal cord injury following COVID-19 vaccination. A 52-year-old female patient developed NMOSD-induced complete spinal cord injury after receiving their third dose of the Pfizer\u2013BioNTech COVID-19 vaccine (BNT162b2). Despite the initial diagnosis of complete spinal cord injury, the patient underwent intensive treatment, including rituximab therapy and rehabilitation. As a result, she made a full recovery and transitioned from the ASIA Impairment Scale(AIS)-A to AIS-E. The remarkable neurological recovery from complete spinal cord injury to functional independence highlights the efficacy of a comprehensive treatment approach. In addition, this case emphasizes the need to recognize NMOSD as a potential adverse outcome of COVID-19 vaccination and emphasizes the importance of early diagnosis, timely intervention, and thorough rehabilitation for optimizing patient results. Further case reports and studies are needed to investigate the association between COVID-19 vaccination and the occurrence of NMOSD.<\/jats:p>","DOI":"10.3390\/jcm13041175","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T10:40:15Z","timestamp":1708339215000},"page":"1175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment and Rehabilitation of a Patient with Neuromyelitis Optica Spectrum Disorder-Induced Complete Spinal Cord Injury Following COVID-19 Vaccination: A Case Report"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8634-8474","authenticated-orcid":false,"given":"Jun-Sang","family":"Han","sequence":"first","affiliation":[{"name":"Department of Rehabilitation Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Mun","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hwan","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-3024","authenticated-orcid":false,"given":"Ae-Ryoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea"},{"name":"Department of Rehabilitation Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-8665","authenticated-orcid":false,"given":"Tae-Du","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea"},{"name":"Department of Rehabilitation Medicine, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"117225","DOI":"10.1016\/j.jns.2020.117225","article-title":"Neuromyelitis optica spectrum disorders","volume":"420","author":"Paul","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Traub, J., H\u00e4usser-Kinzel, S., and Weber, M.S. (2020). Differential Effects of MS Therapeutics on B Cells\u2014Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145021"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00415-017-8596-7","article-title":"What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients","volume":"264","author":"Hamid","year":"2017","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Contentti","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: A comprehensive review of diagnosis and treatment","volume":"35","author":"Chen","year":"2021","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/WCO.0000000000000828","article-title":"Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: Current topics","volume":"33","author":"Fujihara","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.msard.2017.09.015","article-title":"Diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD) in Iran: A consensus guideline and recommendations","volume":"18","author":"Sahraian","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD","volume":"11","author":"Akaishi","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_16","first-page":"6151258","article-title":"Neuromyelitis optica spectrum disorder attack triggered by herpes zoster infection","volume":"2020","author":"Turco","year":"2020","journal-title":"Mult. Scler. Int."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Vanood, A., and Wingerchuk, D. (2019). Systematic review investigating relationship between neuromyelitis optica spectrum disorder (NMOSD) and vaccination (P1. 2-003). Neurology, 92.","DOI":"10.1212\/WNL.92.15_supplement.P1.2-003"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jiph.2020.07.011","article-title":"The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status","volume":"13","author":"Bchetnia","year":"2020","journal-title":"J. Infect. Public Health"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rabail, R., Ahmed, W., Ilyas, M., Rajoka, M.S.R., Hassoun, A., Khalid, A.R., Khan, M.R., and Aadil, R.M. (2022). The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines, 10.","DOI":"10.3390\/vaccines10040488"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"701927","DOI":"10.3389\/fneur.2021.701927","article-title":"Clinical presentation and causes of non-traumatic spinal cord injury: An observational study in emergency patients","volume":"12","author":"Ploner","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/B978-0-444-52137-8.00003-6","article-title":"Clinical diagnosis and prognosis following spinal cord injury","volume":"109","author":"Burns","year":"2012","journal-title":"Handb. Clin. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41393-018-0223-7","article-title":"Non-traumatic spinal cord injury in Norway 2012\u20132016: Analysis from a national registry and comparison with traumatic spinal cord injury","volume":"57","author":"Halvorsen","year":"2019","journal-title":"Spinal Cord"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.autrev.2018.01.001","article-title":"Diagnosis and management of neuromyelitis optica spectrum disorders-An update","volume":"17","author":"Bruscolini","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Arrambide","year":"2016","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1756285617709723","article-title":"Differential diagnosis of neuromyelitis optica spectrum disorders","volume":"10","author":"Kim","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Correale","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104347","DOI":"10.1016\/j.neuint.2018.11.022","article-title":"Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder","volume":"130","author":"Kim","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s13311-021-01055-0","article-title":"Targeting neuromyelitis optica pathogenesis: Results from randomized controlled trials of biologics","volume":"18","author":"Cacciaguerra","year":"2021","journal-title":"Neurotherapeutics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11999-016-5133-4","article-title":"Classifications in brief: American spinal injury association (ASIA) impairment scale","volume":"475","author":"Roberts","year":"2017","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0003-9993(99)90249-6","article-title":"Neurologic recovery after traumatic spinal cord injury: Data from the Model Spinal Cord Injury Systems","volume":"80","author":"Marino","year":"1999","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3171\/2018.10.SPINE18802","article-title":"Neurological recovery following traumatic spinal cord injury: A systematic review and meta-analysis","volume":"30","author":"Khorasanizadeh","year":"2019","journal-title":"J. Neurosurg. Spine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00415-020-09699-2","article-title":"Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort","volume":"267","author":"Tkachuk","year":"2020","journal-title":"J. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1177\/1352458513515085","article-title":"Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset","volume":"20","author":"Collongues","year":"2014","journal-title":"Mult. Scler. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.radcr.2021.09.033","article-title":"Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings","volume":"16","author":"Badrawi","year":"2021","journal-title":"Radiol. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577755","DOI":"10.1016\/j.jneuroim.2021.577755","article-title":"Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"361","author":"Fujimori","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.neurol.2022.11.004","article-title":"Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review","volume":"179","author":"Mirmosayyeb","year":"2023","journal-title":"Rev. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.3389\/fimmu.2020.617089","article-title":"Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: Implications for autoimmune diseases","volume":"11","author":"Vojdani","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/1175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:13Z","timestamp":1760104933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/1175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13041175"],"URL":"https:\/\/doi.org\/10.3390\/jcm13041175","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}